Earth Science Tech Inc. (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, has completed the acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients (APIs) and finished FDA-approved prescription products. The move is part of ETST’s strategy to diversify its revenue streams and strengthen its position in the pharmaceutical supply chain.
Zoolzy, based in Doral, Florida, operates from a 3,684-square-foot facility and specializes in the distribution of APIs and finished pharmaceuticals. This acquisition allows Earth Science Tech’s compounding pharmacies to secure essential raw materials at competitive wholesale prices, which is expected to significantly increase overall profit margins. By integrating Zoolzy’s distribution capabilities, ETST can reduce costs associated with sourcing ingredients from third-party suppliers, thereby enhancing operational efficiency.
Beyond margin improvements, the acquisition broadens ETST’s access to new ingredients, enabling the company to expand its product offerings and potentially enter new therapeutic areas. Additionally, Zoolzy’s existing customer base and distribution network provide ETST with a platform to enter the veterinary market, a complementary vertical with growing demand for pharmaceutical products.
According to a press release, the acquisition delivers value across three growth drivers: expanding overall profit margins, broadening access to new ingredients, and enabling entry into the veterinary market. This strategic move aligns with ETST’s mission to seize opportunities that broaden its telehealth and pharmacy fulfillment platforms into new, complementary verticals.
The integration of Zoolzy is expected to be seamless, as both companies share a focus on regulatory compliance and quality assurance. Earth Science Tech plans to leverage Zoolzy’s expertise in API sourcing to enhance its compounding services, which are used in personalized medicine and telehealth consultations. The company believes this acquisition will not only benefit its bottom line but also improve patient access to essential medications.
Industry analysts see this as a prudent step for ETST to differentiate itself in the competitive healthcare landscape. By controlling more of its supply chain, ETST can mitigate risks associated with price volatility and shortages of critical ingredients. Furthermore, the veterinary market represents an untapped opportunity for the company, given the increasing pet ownership and spending on animal health.
Investors have reacted positively to the news, viewing the acquisition as a sign of management’s proactive approach to growth. Earth Science Tech continues to evaluate other strategic opportunities that could further enhance shareholder value. The company’s newsroom provides updates on its latest developments, and more information about ETST can be found at https://ibn.fm/ETST.
The acquisition of Zoolzy is a clear indication that Earth Science Tech is committed to expanding its footprint in the pharmaceutical industry. With a stronger supply chain and access to new markets, the company is well-positioned to capitalize on emerging trends in healthcare delivery.
